DOCSLIB.ORG

COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021 CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 5th April, 2021 I. Overview of Development and Regulatory Approvals: • 85 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 13 vaccines have received regulatory approvals in various countries, and 16 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • 4 vaccines have been approved by WHO for Emergency Use Listing: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), and Janssen-Cilag. • 4 additional vaccines are expected to be approved by WHO in April – Tables 1 and 3. • There are 3 additional vaccines being considered by WHO but these are at the stage of submitting expressions of interest: Bharat Biotech, Clover Biopharmaceuticals-GSK + Dynavax, and BioCubaFarma (Cuba). • The WHO Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations and background documents are available for vaccines by: Moderna, Pfizer-BioNTech, AstraZeneca-Oxford and Janssen-Cilag at SAGE Interim Guidance. The recommendations provide guidance on the use the vaccines, including use in various groups. • Reports of rare clotting events among vaccinees continue to be assessed by various regulators. The EU's European Medicines Agency (EMA) has stated that there was no evidence to support decisions by regulators to restrict the use of Oxford-AstraZeneca vaccines in some age groups. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made. Table 1: Predicted WHO EUL Approvals in April WHO Predicted Approval Vaccines April - Moderna + NIAID - AstraZeneca-Oxford vaccine (European or UK node) - Sinopharm + Beijing Institute of Biological Products - Sinovac Research and Development (Coronavac) 1 II. Vaccine Deployment in the Caribbean Several Caribbean countries have approved / received COVID-19 vaccines purchases and/or donations. A search of the PAHO Dashboard of COVID-19 Vaccination in the Americas revealed information on COVID- 19 vaccinations by 21 countries of the Caribbean / CARPHA Member States, as of 5th April, 2021 - Figure 1. Caribbean countries that have received COVAX deliveries as of 5th April are: Jamaica, Suriname, Guyana, Bahamas, Belize, and Trinidad and Tobago. Deliveries that are expected this week: Barbados, Antigua and Barbuda, Grenada, St Lucia, St Kitts and Nevis, Bermuda, Dominica, and St Vincent and the Grenadines. FIGURE 1: Number of Doses of COVID-19 Vaccines Administered per 100 population in Member States as of 1st April, 2021 Source of base graphic: Metric Pioneer | CARICOM 2 Table 2: COVID-19 Vaccines Deployed Among CARPHA Member States as of 5th April, 2021 Country Vaccine(s) Total Doses Doses per 100 persons Anguilla AstraZeneca - AZD1222 5,644 30.63 Antigua & Barbuda SII - Covishield 26,424 26.76 Aruba Pfizer-BioNTech – Comirnaty 27,904 26.03 Bahamas SII - Covishield 6,145 1.55 Barbados SII - Covishield 63.711 22.14 Virgin Islands (British) AstraZeneca - AZD1222 7, 162 18.76 Belize SII - Covishield 22,922 5.66 Bermuda Pfizer BioNTech - Comirnaty 37,788 52.48 Cayman Islands Pfizer BioNTech - Comirnaty 49,561 78.54 Dominica SII – Covishield; Beijing CNBG - Inactivated 17,674 23.78 Grenada SII - Covishield 10,305 9.12 Guadeloupe Information not available 24,763 6.19 Guyana SII – Covishield; Beijing CNBG - Inactivated 32,714 4.14 Jamaica SII - Covishield 33, 642 1.13 Martinique Information not available 16,496 4.40 Montserrat AstraZeneca - AZD1222 1,542 28.53 St. Kitts & Nevis SII - Covishield 8,984 16.59 St. Lucia SII - Covishield 22, 357 12.12 St. Vincent & Grenadines SII – Covishield; Gamaleya - Sputnik V 10, 805 9.71 Suriname SII - Covishield 26, 057 4.40 Trinidad & Tobago SII - Covishield 1, 137 0.08 Source: PAHO COVID-19 Vaccination in the Americas Dashboard FIGURE 2: COVID-19 Vaccine Doses per 100 population as of 5th April, 2021 90 78.54 80 70 60 52.48 50 40 30.63 28.53 30 26.76 26.03 23.78 22.14 18.76 20 16.59 12.12 9.71 9.12 10 6.19 5.66 4.4 4.4 4.14 1.55 1.13 0.08 0 3 II. Caribbean Vaccine Introduction Readiness Although some countries have received vaccines, we are monitoring vaccine readiness in the Caribbean to identify areas for strengthening. The PAHO Vaccine Introduction Readiness Tool (VIRAT) as of 5th April, 2021 for the Caribbean is shown below – Figure 3. The countries include Latin and non-Latin Caribbean countries. Indicators of areas that are pending readiness in the Caribbean are: • Safe injection and waste management • Demand generation, community engagement and communication • Human resources and security, and • Vaccination data and information management. FIGURE 3: COVID-19 Vaccine Introduction Readiness Tool Dashboard – Caribbean Region 4 Table 3: COVID-19 Vaccines with Regulatory Approvals by WHO EUL Consideration Developers Vaccine Dosing Storage ¥ Authorized by WHO EUL status and Eligible for CRS Vaccine name Platform anticipated decision review? date: Pzifer & BioNTech mRNA 2 doses WHO EUL + 80 countries including December 2020 Yes – Ship: -80⁰C to -60⁰C; (Tozinameran (INN); BNT162b2 / I.M. United Kingdom, Canada, Mexico, (completed) Recommended Store: -25°C to -15°C COMIRNATY) USA, Chile, Argentina, Switzerland, (2wk) EU, Colombia, Israel, Australia, Brazil, 2⁰C to 8⁰C (12h) Guyana AstraZeneca-Oxford University Recombinant 2 doses 2°C to 8°C (6 mo.) 82 countries including UK, Argentina, In progress: 1st wk Yes (AZD1222) ChAdOx1-S I.M. Mexico, Brazil (local production by April adenoviral Fiocruz), EU, Canada (AZ Canada), vector Colombia, Chile AstraZeneca-Oxford + SK Recombinant 2 doses 2°C to 8°C (6 mo.) WHO EUL + South Korea Approved: 15th Yes - Bioscience (supplier) ChAdOx1-S I.M. For COVAX (Americas) February Recommended (AZD1222) adenoviral vector Serum Institute of India + Recombinant 2 doses 2°C to 8°C (6 mo.) WHO EUL + CRS + 32 countries Approved: 15th Yes - AstraZeneca-Oxford University ChAdOx1-S I.M. including India, Argentina, Bangladesh, February Recommended (AZD1222; Covishield) adenoviral South Africa, Guyana, Canada vector (+VerityPharma) Janssen-Cilag (Johnson & Viral vector 1 dose Sealed: 2-8°C or 9- WHO EUL + 37 countries including: Approved: 12th March; Yes Johnson) (non-replicating) I.M. 25°C (12h) USA, Canada, South Africa, Bahrain, Additional sites (JNJ-78436735) Open: 2-8°C (6h) or Colombia pending 25°C (2h). Moderna & NIAID mNRA-based in 2 doses To ship: -25°C to - 42 countries including Canada, In progress – Mid. Yes (mRNA-1273) lipid I.M. 15°C Switzerland, United Kingdom, United April nanoparticle Sealed: 2-8°C (30d) States, EU, Guyana (LNP) or 9-25°C (12h) Open: 2-25°C (6h) Sinopharm + China National Inactivated 2 doses 2°C to 8°C 28 countries including China, In progress – Mid. No Pharmaceutical Group + virus I.M. Argentina, Bahrain, United Arab April Beijing Institute of Biological Emirates, Egypt, Jordan, Iraq, Products (BBIBP-CorV) Pakistan, Peru, Guyana Sinovac Research and Inactivated 2 doses 2°C to 8°C 19 countries including China, In progress – Mid. No Development Co. Ltd virus I.M. Colombia, Turkey, Indonesia, Brazil, April (CoronaVac) Chile, México, Guyana Gamaleya Research Institute & Adenovirus 2 doses 2°C to 8°C 59 countries including Russia, Information pending No Russian Health Ministry Viral vector I.M. Argentina, Guinea, Bolivia, Venezuela, including completed (Sputnik V) (non-replicating) Paraguay, México, Belize, Guyana, inspections StVincent&Gren CanSino Biological Inc + Adenovirus; 1 dose 2°C to 8°C 4 countries: China, Mexico, Pakistan, Rolling data review No Beijing Institute of Biological Viral vector I.M. Hungary starting in April Products (non-replicating) (Convidicea (Ad5-nCoV)) NOVAVAX (NVX-CoV2373) Protein subunit 2 doses 2°C to 8°C None to date Pending presubmission No I.M. meeting 5 Developers Vaccine Dosing Storage ¥ Authorized by WHO EUL status and Eligible for CRS Vaccine name Platform anticipated decision review? date: Sinopharm + China National Inactivated 2 doses 2°C to 8°C 2 countries: China, United Arab Pending presubmission No Pharma. Group + Wuhan virus I.M. Emirates meeting Institute of Biol. Products Vector State Research Ctre of Peptide vaccine 2 doses 2°C to 8°C Russia, Turkmenistan Pending expression of No Virology and Biotech. I.M. interest (EpiVacCorona) Bharat Biotech + Indian Whole virion 2 2°C to 8°C 5 countries: India, Iran, Zimbabwe, Requested meeting to No Council of Medical Research inactivated Doses Nepal, Mauritius discuss details of (ICMR) I.M. submission/timelines (Covaxin) Clover Biopharmaceuticals Inc. Protein subunit 2 doses 2°C to 8°C None to date In discussion on No + GSK + Dynavax I.M. submission strategy (SCB-2019) and timelines BioCubaFarma - Cuba SARS-CoV-2 None to date In discussion on No (Soberana 01, Soberana 02 spike protein submission strategy Soberana Plus) and timelines ¥ - Storage information is provided primarily for sealed vials. See product information for additional details on storage and handling. References: McGill COVID19 Vaccine Tracker. COVID-19 Vaccines. Updated 2nd April 2021. Available at: https://covid19.trackvaccines.org/. World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Updated 1st April 2021. WHO, Geneva, 2020. Available at: https://www.who.int/teams/regulation-prequalification/eul/covid-19. World Health Organization. Draft landscape of COVID-19 candidate vaccines. WHO, Geneva, 2nd April 2021. Available at: Draft landscape of COVID-19 candidate vaccines (who.int). World Health Organization. Emergency Use Listing Procedure for Vaccines. WHO, Geneva 2021. Available at: https://www.who.int/teams/regulation-prequalification/eul/eul- vaccines. 6 .
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet
    COVID-19 Vaccine FAQ Sheet (updated 1/25/2021) The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available. What kinds of vaccines are available or under development to prevent COVID-19? There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here: • NYTimes Coronavirus Vaccine Tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine- tracker.html • Washington Post Vaccine Tracker: https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update- coronavirus/ The types of vaccines are as follows (January 25, 2021) 1: Table 1: Vaccines Under Development Vaccine Type Compound Name Clinical Trial Notes [Sponsor] Phase mRNA mRNA-1273 Phase 3 Emergency use in [Moderna] U.S., E.U., other countries Approved in Canada BNT162b2 [Pfizer] Phase 2/3 Emergency use in U.S., E.U., other countries Also approved in Canada and other countries Replication- AZD1222 Phase 2/3 Emergency use in defective [AstraZeneca] Britain, India, other adenoviral vector countries (not U.S.) Ad26.COV2.S Phase 3 [Janssen] v.3 1/25/2021 Recombinant- NVX-CoV2373 Phase 3 subunit-adjuvanted [Novavax] protein Recombinant SARS- Phase 1/2 CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK] Inactivated CoVaxin [Bharat Phase 3 Emergency Use in coronavirus Biotech] India BBIBP-CorV Phase 3 Approved China, [Sinopharm] Bahrain, UAE; Emergency use elsewhere (not U.S.) Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St
    Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St. Louis to advance COVID-19 Intranasal Vaccine Technology Hyderabad, India, 23 September 2020: Vaccine Innovator, Bharat Biotech announces today, a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp- adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe. While the Phase I trials will take place in Saint Louis University’s Vaccine & Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad. We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive. Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world.” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated. This intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal Cell and in an editorial in Nature.
    [Show full text]
  • Editorial 10.5005/Ijmb-24-3-Iv
    Editorial 10.5005/ijmb-24-3-iv COVID-19 Vaccines: Lets Go for It SARS CoV-2, also christened as COVID-19 is an acute respiratory illness caused by a novel coronavirus which originated from Wuhan China in 2019 and within a short span affected virtually each and every country around the globe, throwing healthcare preparedness and economy out of gear. The world was faced with a pandemic leading to overcrowded hospitals and overflowing mortuaries. Lockdowns imposed in countries jeopardized routine life never to normalize again. India has been among the top three countries with the maximum number of afflicted people. Thankfully , our statistics with respect to mortality is better as compared to the western world. The last year 2020 was completely COVIDISED if we may say so. The world economy is in doldrums and the health infrastructure is overstretched and fatigued. Everytime we feel that the disease is under control, the virus cleverly mutates to become more infective and develops increased ability to escape the immune surveillance. Efforts to develop a vaccine against this scourge were initiated at a war footing across the globe. A number of vaccines were approved for emergency use since the scientific committee didn’t have the time to wait further. In India, two vaccines- Covaxin and Covishield have been approved by the Government of India for mass vaccination. The mammoth program was initiated with first preference for the healthcare workers and frontline warriors. In the next phases, elderly population followed by the rest of the population in a phased manner was planned. It is really incredible and praiseworthy about the immaculate planning and implementation of the initiative in our country where the diversity is both a boon as well as bane.
    [Show full text]
  • COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS What You Need to Know
    THE REPUBLIC OF UGANDA MINISTRYMINISTRY OF HEALTH COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS What You Need to Know Introduction This document contains the frequently asked questions and answers to provide you with information on the COVID-19 vaccines and why it is important for you to get vaccinated, or encourage those around you to get vaccinated as long as they are eligible. General information about COVID-19 and COVID-19 Vaccine 1. What is the Coronavirus Disease of 2019 (COVID-19) and how does it spread? COVID-19 is an infectious respiratory disease caused by the coronavirus, SARS-CoV-2. The World Health Organisation (WHO) first learned of this new virus from cases in Wuhan city in China on 31st December 2019. The virus can spread from an infected person’s mouth or nose in small liquid particles (droplets) when they cough, sneeze, talk, sing or breathe heavily. The main way the virus spreads is when people are in direct or close contact (less than 1 meter) with an infected person. 1 2. What are the signs and symptoms of COVID-19 infection? • The most common symptoms of COVID-19 are fever, dry cough, and fatigue. • Other symptoms that are less common include loss of taste or smell, nasal congestion, conjunctivitis (red eyes), sore throat, headache, muscle or joint pain, skin rash, nausea or vomiting, diarrhea, chills or dizziness. Symptoms are usually mild. • Some people may get infected and progress to severe disease. Symptoms of severe COVID-19 disease include shortness of breath, loss of appetite, confusion, persistent pain or pressure in the chest, and high temperature (above 38°C).
    [Show full text]
  • An Overview of COVID Vaccine Clinical Trial Results & Some Challenges
    An overview of COVID vaccine clinical trial results & some challenges DCVMN Webinar December 8th, 2020 Access to COVID-19 tools ACCESSACCESS TO TOCOVID-19 COVID-19 TOOLS TOOLS (ACT) (ACT) ACCELERATOR ACCELERATOR (ACT) accelerator A GlobalA GlobalCollaboration Collaboration to Accelerate tothe AccelerateDevelopment, the Production Development, and Equitable Production Access to New and Equitable AccessCOVID-19 to New diagnostics, COVID-19 therapeutics diagnostics, and vaccines therapeutics and vaccines VACCINES DIAGNOSTICS THERAPEUTICS (COVAX) Development & Manufacturing Led by CEPI, with industry Procurement and delivery at scale Led by Gavi Policy and allocation Led by WHO Key players SOURCE: (ACT) ACCELERATOR Commitment and Call to Action 24th April 2020 ACT-A / COVAX governance COVAX COORDINATION MEETING CEPI Board Co-Chair: Jane Halton Co-Chair: Dr. Ngozi Gavi Board Workstream leads + DCVMN and IFPMA-selected Reps As needed – R&D&M Chair; COVAX IPG Chair Development & Manufacturing Procurement and delivery Policy and allocation (COVAX) at scale Led by (with industry) Led by Led by R&D&M Investment Committee COVAX Independent Product Group Technical Review Group Portfolio Group Vaccine Teams SWAT teams RAG 3 COVAX SWAT teams are being set up as a joint platform to accelerate COVID- 19 Vaccine development and manufacturing by addressing common challenges together Timely and targeted Multilateral Knowledge-based Resource-efficient Addresses specific cross- Establishes a dialogue Identifies and collates Coordinates between developer technical and global joint effort most relevant materials different organizations/ challenges as they are across different COVID-19 and insights across the initiatives to limit raised and/or identified vaccines organizations broader COVID-19 duplications and ensure on an ongoing basis (incl.
    [Show full text]
  • The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia's Vaccine
    Article The Fast Approval and Slow Rollout of Sputnik V: Why Is Russia’s Vaccine Rollout Slower than That of Other Nations? Elza Mikule 1,*,† , Tuuli Reissaar 1,† , Jennifer Villers 1,† , Alain Simplice Takoupo Penka 1,† , Alexander Temerev 2 and Liudmila Rozanova 2 1 Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland; [email protected] (T.R.); [email protected] (J.V.); [email protected] (A.S.T.P.) 2 Institute of Global Health, University of Geneva, 1202 Geneva, Switzerland; [email protected] (A.T.); [email protected] (L.R.) * Correspondence: [email protected] † These authors contributed equally. Abstract: The emergence of the SARS-CoV-2 pandemic in the beginning of 2020 led to the deployment of enormous amounts of resources by different countries for vaccine development, and the Russian Federation was the first country in the world to approve a COVID-19 vaccine on 11 August 2020. In our research we sought to crystallize why the rollout of Sputnik V has been relatively slow considering that it was the first COVID-19 vaccine approved in the world. We looked at production capacity, at the number of vaccine doses domestically administered and internationally exported, and at vaccine hesitancy levels. By 6 May 2021, more first doses of Sputnik V had been administered Citation: Mikule, E.; Reissaar, T.; abroad than domestically, suggesting that limited production capacity was unlikely to be the main Villers, J.; Takoupo Penka, A.S.; reason behind the slow rollout. What remains unclear, however, is why Russia prioritized vaccine Temerev, A.; Rozanova, L.
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student
    INTERNATIONAL STUDENT COVID VACCINE LIST and COMMUNICATION Dear International Student We have provided a list of Selected Countries to help you find the COVID-19 vaccine you may have already received. Please see the “WHO” list below to find your COVID-19 vaccine, and if it has been APPROVED. And please upload your record following these directions: https://youtu.be/wvBGeRqIMHc If you see that your vaccine HAS NOT yet been approved by “WHO”, you may be required to receive an approved COVID-19 vaccine and upload those records to meet UC campus policy and requirements. Many US Airports are now providing COVID-19 vaccine on-site. Here is a list of several California Airports that you may arriving where you may receive a vaccine IMMEDIATELY upon your entry into the U.S. LAX – Los Angeles https://www.flylax.com/TravelSafely SNA – Orange County https://hoagurgentcare.com/airport/ SFO – San Francisco https://www.flysfo.com/travel-well/vaccination-site-sfo If you have any additional questions or concerns, please call (949)824-2300 for support. THANK YOU for helping to ensure UCI continues to be a SAFE and HEALTHY Campus! Dr Chang INDIA SOUTH KOREA TAIWAN INDONESIA VIETNAM JAPAN Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Oxford–AstraZeneca Oxford-AstraZeneca Sinovac Sputnik V Pfizer–BioNTech Covishield Pfizer–BioNTech Oxford–AstraZeneca Oxford–AstraZeneca Sinopharm Janssen Sinopharm Moderna Pfizer–BioNTech Moderna Pfizer–BioNTech Moderna Moderna Covaxin Novavax Moderna Johnson & Johnson Oxford–AstraZeneca Sputnik V Novavax Nanocovax Johnson & Johnson Sputnik V COVIVAC Sputnik V CanSino Vabiotech MVC-COV1901 ZyCoV-D Corbevax Covovax .
    [Show full text]
  • COVID-19 Vaccine Weekly Intel Report
    COVID-19 Vaccine Weekly Intel Report Science, trial forecast, production and news analysis April 23rd - Prepared for BIO, DCVMN, IFPMA © 2021 Airfinity Ltd | Private & Confidential. © 2021 Airfinity Ltd | Private & Confidential Over 9 billion doses could be produced this year An analysis of forecasted production of vaccine candidates ForecasteD proDuction 9,889,406,370 8,478,587,508 7,206,503,589 5,982,385,185 4,871,966,540 3,815,817,604 2,870,502,904 2,080,496,478 1,388,902,344 830,218,085 200,715,588 425,929,684 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 © 2021 Airfinity Ltd | Private & Confidential 2 Over 9 billion doses could be produced this year An analysis of forecasted production of vaccine candidates split by candidate Ad26COVS1 (J&J) mRNA-1273 (MoDerna) Ad5-nCoV (CanSino) MVC-COV1901 (MeDigen/Dynavax) AZD1222 (University of OxforD/AstraZeneca) NasoVAX (Altimmune) BBIBP-CorV (Beijing/Sinopharm) NVX-CoV2373 (Novavax) BNT162b2 (Pfizer/BioNTech) S-268019 (UMN Pharma) CoronaVac (Sinovac) SCB-2019 (Clover/Dynavax) COVAXIN (Bharat/ICMR/NIV) Sputnik V (Gamaleya Research Institute) CoviVac (Chumakov FeDeral Scientific Center) UB-612 (Covaxx) CVnCoV (Curevac) Vaccine (Anhui Zhifei) 9,889,406,370 EpiVacCorona (VECTOR) Vaccine (MeDicago/GSK) GRAD-COV2 (Reithera/LeukoCare/Univercells ) Vaccine (Sanofi/GSK) 8,478,587,508 INO-4800 (Inovio Pharma) VLA2001 (Valneva/Dynavax) LUNAR-COV19 (Arcturus) ZyCoV-D (ZyDus Cadila) 7,206,503,589 5,982,385,185 4,871,966,540 3,815,817,604 2,870,502,904 2,080,496,478
    [Show full text]
  • India: the World's Pharmacy Expands Its Reach in Global Health
    New York | New Delhi | Rio de Janeiro Nairobi | Johannesburg | London India: The World’s Pharmacy Expands Its Reach in Global Health March 2021 This white paper was last updated on 1 March 2021 Global Health Strategies 18/1, 2nd Floor Shaheed Bhawan, Aruna Asaf Ali Marg, New Delhi, 110 067 www.globalhealthstrategies.com Twitter: @GHS Contents Executive Summary 02 India’s response to COVID-19 03 ∙ Pharmaceuticals and Biosimilars 04 ∙ Vaccines 05 ∙ Diagnostics 06 Evolution of India’s pharmaceutical industry 07 ∙ Milestones 08 Case Studies ∙ Hepatitis B Vaccine 10 ∙ Anti-retroviral Drugs 11 ∙ MenAfriVac 12 ∙ Complex Generics 13 ∙ Insulin 14 ∙ Monoclonal Antibodies 15 ∙ Vaccine for Rotavirus 16 ∙ Typhoid Conjugate Vaccine 17 Conclusion: Looking Forward 18 Executive Summary India’s pharmaceutical industry is already playing a pivotal role in the scale-up of pharmaceuticals and diagnostics to combat the global COVID-19 pandemic. It is poised to play an even more dominant role as biological products – preventive vaccines and cutting-edge biotechnology such as monoclonal antibodies– come to the fore. Even before the pandemic, Indian manufacturers produced vast quantities of generic antiviral drugs that turned HIV from a death sentence to a chronic manageable condition in developing countries. India’s global dominance in generic drugs and vaccine manufacturing has earned it the label “Pharmacy of the World”. COVID-19 only strengthens the case for this moniker. So far, India has supplied medicines to 133 countries to fight the pandemic. Six Indian manufacturers have been granted royalty-free licenses by Gilead to manufacture the first antiviral drug approved by the U.S.
    [Show full text]